

## 8 Literatur

- [1] Grundy SM, Arky R, Bray GA, Brown WV, Ernst ND, Kwiterovich PO Jr, Mattson F, Weidman WH, Schonfeld G, Strong JP, Weinberger M. Coronary risk factor statement for the American public. A statement of the nutrition committee. *Circulation*. 1985 Nov;72(5):1135A-1139A.
- [2] Lusic AJ. Atherosclerosis. *Nature*. 2000 Sep 14;407(6801):233-41.
- [3] Gruntzig A. Transluminal dilatation of coronary-artery stenosis. *Lancet*. 1978 Feb 4;1(8058):263.
- [4] Smith SC Jr. Primary and secondary prevention of heart disease: can we curb the global epidemic? *Trans Am Clin Climatol Assoc*. 2001;112:89-95; discussion 95-8.
- [5] Mannebach H, Horstkotte D; Arbeitsgruppen Interventionelle Kardiologie und Angiologie; Deutsche Gesellschaft für Kardiologie, Herz- und Kreislaufforschung. [19th report of performance statistics of heart catheterization laboratories in Germany. Results of a collaborative survey by the Committee of Clinical Cardiology and the Interventional Cardiology (for ESC) and Angiology Study Groups of the German Society of Cardiology--Heart and Cardiovascular Research in 2002] *Z Kardiol*. 2004 Dec;93(12):1022-5. German.
- [6] Fattori R, Piva T. Drug-eluting stents in vascular intervention. *Lancet*. 2003 Jan 18;361(9353):247-9.
- [7] Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, Virmani R. Pathology of acute and chronic coronary stenting in humans. *Circulation*. 1999 Jan 5-12;99(1):44-52.
- [8] Hoffmann R, Mintz GS, Dussailant GR, Popma JJ, Pichard AD, Satler LF, Kent KM, Griffin J, Leon MB. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. *Circulation*. 1996 Sep 15;94(6):1247-54.
- [9] Mintz GS, Hoffmann R, Mehran R, Pichard AD, Kent KM, Satler LF, Popma JJ, Leon MB. In-stent restenosis: the Washington Hospital Center experience. *Am J Cardiol*. 1998 Apr 9;81(7A):7E-13E.

- [10] Mudra H, Regar E, Klauss V, Werner F, Henneke KH, Sbarouni E, Theisen K.  
Serial follow-up after optimized ultrasound-guided deployment of Palmaz-Schatz stents. In-stent neointimal proliferation without significant reference segment response.  
Circulation. 1997 Jan 21;95(2):363-70.
- [11] Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A.  
Vessel size and long-term outcome after coronary stent placement.  
Circulation. 1998 Nov 3;98(18):1875-80.
- [12] Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A.  
Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.  
J Am Coll Cardiol. 1998 Dec;32(7):1866-73.
- [13] Kastrati A, Elezi S, Dirschinger J, Hadamitzky M, Neumann FJ, Schomig A.  
Influence of lesion length on restenosis after coronary stent placement.  
Am J Cardiol. 1999 Jun 15;83(12):1617-22.
- [14] Kastrati A, Mehilli J, Dirschinger J, Pache J, Ulm K, Schuhlen H, Seyfarth M, Schmitt C, Blasini R, Neumann FJ, Schomig A.  
Restenosis after coronary placement of various stent types.  
Am J Cardiol. 2001 Jan 1;87(1):34-9.
- [15] Kastrati A, Schomig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M, Wehinger A, Hausleiter J, Walter H, Neumann FJ.  
Predictive factors of restenosis after coronary stent placement.  
J Am Coll Cardiol. 1997 Nov 15;30(6):1428-36
- [16] Kobayashi Y, De Gregorio J, Kobayashi N, Akiyama T, Reimers B, Finci L, Di Mario C, Colombo A.  
Stented segment length as an independent predictor of restenosis.  
J Am Coll Cardiol. 1999 Sep;34(3):651-9.
- [17] Kolodgie FD, John M, Khurana C, Farb A, Wilson PS, Acampado E, Desai N, Soon-Shiong P, Virmani R.  
Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel.  
Circulation. 2002 Sep 3;106(10):1195-8.
- [18] Babapulle MN, Eisenberg MJ.  
Coated stents for the prevention of restenosis: Part I.  
Circulation. 2002 Nov 19;106(21):2734-40.
- [19] Babapulle MN, Eisenberg MJ.  
Coated stents for the prevention of restenosis: Part II.  
Circulation. 2002 Nov 26;106(22):2859-66.

- [20] Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ.  
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.  
Lancet. 2004 Aug 14-20;364(9434):583-91.
- [21] Birkenhauer P, Yang Z, Gander B.  
Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives.  
J Pharm Pharmacol. 2004 Nov;56(11):1339-56.
- [22] Scheller B  
Medikamentenbeschichtete Stents, Wo stehen wir 2004 ?  
Z Kardiol 93:646-648 (2204) DOI 10.1007/s00392-004-0145-6
- [23] Sousa JE, Serruys PW, Costa MA.  
New frontiers in cardiology: drug-eluting stents: Part I.  
Circulation. 2003 May 6;107(17):2274-9.
- [24] Sousa JE, Serruys PW, Costa MA.  
New frontiers in cardiology: drug-eluting stents: Part II.  
Circulation. 2003 May 13;107(18):2383-9.
- [25] Tanabe K, Regar E, Lee CH, Hoye A, van der Giessen WJ, Serruys PW.  
Local drug delivery using coated stents: new developments and future perspectives.  
Curr Pharm Des. 2004;10(4):357-67.
- [26] Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G.  
Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis.  
Circulation. 2004 Aug 17;110(7):810-4. Epub 2004 Aug 9.
- [27] Scheller B, Speck U, Romeike B, Schmitt A, Sovak M, Bohm M, Stoll HP.  
Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model.  
Eur Heart J. 2003 Aug;24(15):1462-7.
- [28] Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G.  
Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation.  
J Am Coll Cardiol. 2003 Oct 15;42(8):1415-20.
- [29] Nakamura M, Wada M, Hara H, Kozuma K, Otsuka Y, Miyazaki S.  
Angiographic and clinical outcomes of a pharmacokinetic study of sirolimus-eluting stents: lesson from restenosis cases.  
Circ J. 2005 Oct;69(10):1196-201.

- [30] Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT.  
Plant antitumor agents. VI. The isolation and structure of taxol, a novel  
antileukemic and antitumor agent from *Taxus brevifolia*.  
Am Chem Soc. 1971 May 5;93(9):2325-7.
- [31] Rowinsky EK, Donehower RC.  
Paclitaxel (taxol)  
N Engl J Med. 1995 Apr 13;332(15):1004-14. Review. Erratum in: N Engl J  
Med 1995 Jul 6;333(1):75.
- [32] Schiff PB, Fant J, Horwitz SB.  
Promotion of microtubule assembly in vitro by taxol.  
Nature. 1979 Feb 22;277(5698):665-7.
- [33] Schneider B (1996)  
Taxol. Ein Arzneimittel aus der Rinde der Eibe.  
Deutsche Apotheker Zeitung 134. Jahrg. 19-30
- [34] F Spencer CM, Faulds D.  
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties  
and therapeutic potential in the treatment of cancer.  
Drugs. 1994 Nov;48(5):794-847.
- [35] F Denis, J., Correa, A. G., Greene, A. E. .  
An Improved Synthesis Of The Taxol Side Chain And Of Rp 56976.  
Journal Of The Organic Chemistry, v. 55, p. 1957-1959, 1990
- [36] F Schiff PB, Horwitz SB.  
Taxol stabilizes microtubules in mouse fibroblast cells.  
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5.
- [37] Rowinsky EK, Cazenave LA, Donehower RC.  
Taxol: a novel investigational antimicrotubule agent.  
J Natl Cancer Inst. 1990 Aug 1;82(15):1247-59.
- [38] Parness J, Horwitz SB.  
Taxol binds to polymerized tubulin in vitro.  
J Cell Biol. 1981 Nov;91(2 Pt 1):479-87.
- [39] Manfredi JJ, Parness J, Horwitz SB.  
Taxol binds to cellular microtubules.  
J Cell Biol. 1982 Sep;94(3):688-96
- [40] Kumar N.  
Taxol-induced polymerization of purified tubulin. Mechanism of action.  
J Biol Chem. 1981 Oct 25;256(20):10435-41.
- [41] Wilson L, Miller HP, Farrell KW, Snyder KB, Thompson WC, Purich DL.  
Taxol stabilization of microtubules in vitro: dynamics of tubulin addition and  
loss at opposite microtubule ends.  
Biochemistry. 1985 Sep 10;24(19):5254-62.

- [42] Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorcken JB, Pinedo HM, Beijnen JH.  
Taxanes: a new class of antitumor agents.  
Cancer Invest. 1995;13(4):381-404.
- [43] Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD, Leyland-Jones B.  
Hypersensitivity reactions from taxol.  
J Clin Oncol. 1990 Jul;8(7):1263-8.
- [44] Axel DI, Kunert W, Goggelmann C, Oberhoff M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Koveker G, Karsch KR.  
Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.  
Circulation. 1997 Jul 15;96(2):636-45.
- [45] Oberhoff M, Kunert W, Herdeg C, Kuttner A, Kranzhofer A, Horch B, Baumbach A, Karsch KR.  
Inhibition of smooth muscle cell proliferation after local drug delivery of the antimetabolic drug paclitaxel using a porous balloon catheter.  
Basic Res Cardiol. 2001 May-Jun;96(3):275-82.
- [46] Herdeg C, Oberhoff M, Baumbach A, Blattner A, Axel DI, Schroder S, Heinle H, Karsch KR.  
Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo.  
J Am Coll Cardiol. 2000 Jun;35(7):1969-76.
- [47] Heldman AW, Cheng L, Jenkins GM, Heller PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, Bunge KE, Kinsella JL, Sollott SJ, Lakatta EG, Brinker JA, Hunter WL, Froehlich JP.  
Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.  
Circulation. 2001 May 8;103(18):2289-95.
- [48] Baumbach A, Herdeg C, Kluge M, Oberhoff M, Lerch M, Haase KK, Wolter C, Schroder S, Karsch KR.  
Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall.  
Catheter Cardiovasc Interv. 1999 May;47(1):102-6.
- [49] Jordan MA, Toso RJ, Thrower D, Wilson L.  
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.  
Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552-6.
- [50] van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A.  
Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.  
Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18.

- [51] Stacul F.  
Current iodinated contrast media.  
Eur Radiol. 2001;11(4):690-7.
- [52] Palmer FJ.  
The RACR survey of intravenous contrast media reactions. Final report.  
Australas Radiol. 1988 Nov;32(4):426-8.
- [53] Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K.  
Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media.  
Radiology. 1990 Jun;175(3):621-8.
- [54] Kinnison ML, Powe NR, Steinberg EP.  
Results of randomized controlled trials of low-versus high-osmolality contrast media.  
Radiology. 1989 Feb;170(2):381-9.
- [55] Wang YX, Hussain SM, Krestin GP.  
Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging.  
Eur Radiol. 2001;11(11):2319-31.
- [56] Taupitz M, Schmitz S, Hamm B.  
Superparamagnetic iron oxide particles: current state and future development  
Rofo. 2003 Jun;175(6):752-65
- [57] Hahn PF, Stark DD, Lewis JM, Saini S, Elizondo G, Weissleder R, Fretz CJ, Ferrucci JT.  
First clinical trial of a new superparamagnetic iron oxide for use as an oral gastrointestinal contrast agent in MR imaging.  
Radiology. 1990 Jun;175(3):695-700.
- [58] Reimer P, Rummeny EJ, Daldrup HE, Balzer T, Tombach B, Berns T, Peters PE.  
Clinical results with Resovist: a phase 2 clinical trial.  
Radiology. 1995 May;195(2):489-96.
- [59] Taupitz M, Schnorr J, Wagner S, Abramjuk C, Pilgrimm H, Kivelitz D, Schink T, Hansel J, Laub G, Hunigen H, Hamm B.  
Coronary MR angiography: experimental results with a monomer-stabilized blood pool contrast medium.  
Radiology. 2002 Jan;222(1):120-6.
- [60] Anzai Y, Blackwell KE, Hirschowitz SL, Rogers JW, Sato Y, Yuh WT, Runge VM, Morris MR, McLachlan SJ, Lufkin RB.  
Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer.  
Radiology. 1994 Sep;192(3):709-15.

- [61] Anzai Y, Brunberg JA, Lufkin RB.  
Imaging of nodal metastases in the head and neck.  
J Magn Reson Imaging. 1997 Sep-Oct;7(5):774-83.
- [62] Reimer P, Balzer T.  
Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications.  
Eur Radiol. 2003 Jun;13(6):1266-76. Epub 2002 Nov 1.
- [63] Nolte I, Vince GH, Maurer M, Herbold C, Goldbrunner R, Solymosi L, Stoll G, Bendszus M.  
Iron particles enhance visualization of experimental gliomas with high-resolution sonography.  
AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1469-74.
- [64] Enochs WS, Harsh G, Hochberg F, Weissleder R.  
Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide agent.  
J Magn Reson Imaging. 1999 Feb;9(2):228-32.
- [65] Speck U, Scheller B, Abramjuk C, Grossmann S, Mahnkopf D, Simon O.  
Inhibition of restenosis in stented porcine coronary arteries: uptake of Paclitaxel from angiographic contrast media.  
Invest Radiol. 2004 Mar;39(3):182-6.
- [66] Lincoff AM, Topol EJ, Ellis SG.  
Local drug delivery for the prevention of restenosis. Fact, fancy, and future.  
Circulation. 1994 Oct;90(4):2070-84.
- [67] Serruys PW, Foley DP, Pieper M, Kleijne JA, de Feyter PJ; TRAPIST investigators.  
The TRAPIST Study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound.  
Eur Heart J. 2001 Oct;22(20):1938-47. Erratum in: Eur Heart J 2002 Jul;23(13):1066.
- [68] Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ.  
A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.  
Eur Heart J. 1999 Jan;20(1):58-69.

- [69] Serruys PW, Foley DP, Hofling B, Puel J, Glogar HD, Seabra-Gomes R, Goicolea J, Coste P, Rutsch W, Katus H, Bonnier H, Wijns W, Betriu A, Hauf-Zachariou U, van Swijndregt EM, Melkert R, Simon R.  
Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial.  
Circulation. 2001 Feb 27;103(8):E51-2.
- [70] Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P, Fischman D, Goldberg S, Brinker JA, Zeiher AM, Shapiro LM, Willerson J, Davis BR, Ferguson JJ, Popma J, King SB 3rd, Lincoff AM, Tcheng JE, Chan R, Granett JR, Poland M.  
Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial.  
Circulation. 2002 Sep 3;106(10):1243-50.
- [71] Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA; SES-SMART Investigators.  
Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.  
JAMA. 2004 Dec 8;292(22):2727-34.
- [72] Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW.  
Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.  
Circulation. 2001 Jan 16;103(2):192-5.
- [73] Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW.  
Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.  
Circulation. 2001 Oct 23;104(17):2007-11.
- [74] Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW.  
Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries.  
Circulation. 2003 Jan 28;107(3):381-3.



- [75] Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions.  
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.  
N Engl J Med. 2002 Jun 6;346(23):1773-80.
- [76] Regar E, Serruys PW, Bode C, Holubarsch C, Guermonez JL, Wijns W, Bartorelli A, Constantini C, Degertekin M, Tanabe K, Disco C, Wuelfert E, Morice MC; RAVEL Study Group.  
Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size.  
Circulation. 2002 Oct 8;106(15):1949-56.
- [77] Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC; RAVEL Study Group.  
Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RANDOMIZED study with the sirolimus-eluting VELOCITY balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial.  
Circulation. 2002 Aug 13;106(7):798-803.
- [78] Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, Morice MC, Ligthart JM, de Feyter PJ.  
Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis.  
Circulation. 2003 Dec 2;108(22):2747-50. Epub 2003 Nov 24.
- [79] Abizaid A, Costa MA, Blanchard D, Albertal M, Eltchaninoff H, Guagliumi G, Geert-Jan L, Abizaid AS, Sousa AG, Wuelfert E, Wietze L, Sousa JE, Serruys PW, Morice MC; Ravel Investigators.  
Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial.  
Eur Heart J. 2004 Jan;25(2):99-100.
- [80] Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators.  
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.  
N Engl J Med. 2003 Oct 2;349(14):1315-23.

- [81] Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. *Circulation*. 2004 Feb 10;109(5):634-40.
- [82] Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRollmUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. *Circulation*. 2004 May 18;109(19):2273-8. Epub 2004 May 3.
- [83] Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt G; E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). *Lancet*. 2003 Oct 4;362(9390):1093-9.
- [84] Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ; C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). *J Am Coll Cardiol*. 2004 Mar 17;43(6):1110-5.
- [85] Colombo A, Moses JW, Morice MC, Ludwig J, Holmes DR Jr, Spanos V, Louvard Y, Desmedt B, Di Mario C, Leon MB. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. *Circulation*. 2004 Mar 16;109(10):1244-9. Epub 2004 Feb 23.
- [86] Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, Arampatzis CA, Hoye A, van Duuren M, Sianos G, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. *J Am Coll Cardiol*. 2003 Jun 4;41(11):2093-9.
- [87] Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, van der Giessen WJ, de Feyter PJ. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. *Circulation*. 2004 Jan 20;109(2):190-5. Epub 2003 Dec 22.

- [88] Doggrell SA,  
Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis  
Expert Opin. Pharmacother. (2004) 5 (11): 2209-2220
- [89] Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME.  
TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions.  
Circulation. 2003 Jan 7;107(1):38-42.
- [90] Buellesfeld L, Gerckens U, Muller R, Grube E.  
Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.  
Z Kardiol. 2003 Oct;92(10):825-32.
- [91] Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME; TAXUS II Study Group.  
Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.  
Circulation. 2003 Aug 19;108(7):788-94. Epub 2003 Aug 4.
- [92] Tanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, Chan C, Munzel T, Belardi J, Ruzyllo W, Bilodeau L, Kelbaek H, Ormiston J, Dawkins K, Roy L, Strauss BH, Disco C, Koglin J, Russell ME, Colombo A; TAXUS II Study Group.  
Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial.  
Circulation. 2004 Jan 20;109(2):196-200. Epub 2003 Dec 22.
- [93] Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators.  
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.  
N Engl J Med. 2004 Jan 15;350(3):221-31.
- [94] Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators.  
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.  
Circulation. 2004 Apr 27;109(16):1942-7. Epub 2004 Apr 12.

- [95] Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E, Degertekin M, Ligthart JM, Disco C, Backx B, Russell ME.  
TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation.  
Circulation. 2003 Feb 4;107(4):559-64.
- [96] Stone GW, Ellis SG, O'Shaughnessy CD, Martin SL, Satler L, McGarry T, Turco MA, Kereiakes DJ, Kelley L, Popma JJ, Russell ME; TAXUS V ISR Investigators.  
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.  
JAMA. 2006 Mar 15;295(11):1253-63. Epub 2006 Mar 12.
- [97] Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell ME; TAXUS VI Investigators.  
Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.  
Circulation. 2005 Nov 22;112(21):3306-13. Epub 2005 Nov 14.
- [98] Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schuhlen H, Schmitt C, Dirschinger J, Schomig A; ISAR-DESIRE Study Investigators.  
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.  
JAMA. 2005 Jan 12;293(2):165-71.
- [99] Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Böhm M, Speck U.  
Treatment of Coronary In-stent Restenosis with a Paclitaxel-coated Balloon Catheter.  
NEJM in press.
- [100] Speck U, Scheller B, Abramjuk C, Breitwieser C, Dobberstein J, Boehm M, Hamm B.  
Neointima inhibition: comparison of effectiveness of non-stent-based local drug delivery and a drug-eluting stent in porcine coronary arteries.  
Radiology. 2006 Aug;240(2):411-8.
- [101] Parvez Z, Moncada R, Messmore HL, Fareed J.  
Ionic and non-ionic contrast media interaction with anticoagulant drugs.  
Acta Radiol Diagn (Stockh). 1982;23(4):401-4.
- [102] Jackson DM, Dawson P.  
Current usage of contrast agents, anticoagulant and antiplatelet drugs in angiography and angioplasty in the UK.  
Clin Radiol. 1995 Oct;50(10):699-704.

- [103] Mross K, Hollander N, Hauns B, Schumacher M, Maier-Lenz H.  
The pharmacokinetics of a 1-h paclitaxel infusion.  
Cancer Chemother Pharmacol. 2000;45(6):463-70.
- [104] Jaehwi Lee, Sang Cheon Lee, Ghanashyam Acharya, Ching-jeer Chang,  
Kinam Park,  
Hydrotropic Solubilization of Paclitaxel: Analysis of Chemical Structures for  
Hydrotropic Property,  
Pharmaceutical Research, Vol. 20, No. 7, July 2003
- [105] Cho YW, Lee J, Lee SC, Huh KM, Park K.  
Hydrotropic agents for study of in vitro paclitaxel release from polymeric  
micelles.  
J Control Release. 2004 Jun 18;97(2):249-57.